Home » Stocks » TPTX

Turning Point Therapeutics, Inc. (TPTX)

Stock Price: $104.42 USD 4.34 (4.34%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
After-hours: $106.00 +1.58 (1.51%) Oct 28, 4:47 PM

Stock Price Chart

Key Info

Market Cap 4.40B
Revenue (ttm) n/a
Net Income (ttm) -133.65M
Shares Out 42.17M
EPS (ttm) -3.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $104.42
Previous Close $100.08
Change ($) 4.34
Change (%) 4.34%
Day's Open 100.08
Day's Range 98.00 - 106.90
Day's Volume 965,089
52-Week Range 31.30 - 122.85

More Stats

Market Cap 4.40B
Enterprise Value 3.70B
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 42.17M
Float 36.19M
EPS (basic) -3.59
EPS (diluted) -3.74
FCF / Share -2.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.76M
Short Ratio 7.14
Short % of Float 10.38%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.04
Revenue n/a
Operating Income -140.56M
Net Income -133.65M
Free Cash Flow -84.05M
Net Cash 705.97M
Net Cash / Share 16.74
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -13.73%
ROE -27.88%
ROIC -43.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 9
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(12.47% upside)
Current: $104.42
Target: 117.44
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-77.72-25.64-16.73
Net Income-72.13-24.79-16.59
Shares Outstanding24.123.393.34
Earnings Per Share-2.99-7.31-4.97
Operating Cash Flow-57.76-23.53-12.64
Capital Expenditures-1.74-0.30-0.09
Free Cash Flow-59.50-23.84-12.73
Cash & Equivalents40910145.03
Total Debt5.06--
Net Cash / Debt40410145.03
Book Value404-48.41-24.84
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Turning Point Therapeutics, Inc.
Country United States
Employees 109
CEO Athena Countouriotis

Stock Information

Ticker Symbol TPTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TPTX
IPO Date April 17, 2019


Turning Point Therapeutics, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.